MetaCap

Atossa Therapeutics (ATOS) vs Pasithea Therapeutics (KTTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed Atossa Therapeutics (ATOS) over the past year, gaining 63.9% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.4% for KTTA. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $15.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATOS-86.37%KTTA+63.94%
+428%+159%-111%
Nov 21, 20251 yearNov 20, 2026
ATOS-95.48%KTTA-98.99%
+78%-15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATOS versus KTTA key metrics
MetricATOSKTTA
Share price$1.60$0.4787
Market cap$15.92M$17.59M
1-day change-8.86%-0.48%
YTD return-81.98%-62.89%
1-year return-86.37%+63.94%
5-year return-95.34%-99.40%
EPS (TTM)$-3.92$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.77M$-20.43M
52-week high$14.85$2.06
52-week low$1.59$0.32
Distance from 52-week high-89.26%-76.76%
Analyst consensusstrong_buynone
Avg. price target upside+1091.22%+526.70%
Average volume68.00K705.64K
Shares outstanding9.98M36.75M
Employees165
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed ATOS by 150.3 percentage points over the past year.

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

ATOS vs KTTA FAQ

Which is bigger, Atossa Therapeutics or Pasithea Therapeutics?

Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $15.92M for Atossa Therapeutics (ATOS).

Which stock has performed better over the past year, ATOS or KTTA?

KTTA returned +63.94% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.

Are Atossa Therapeutics and Pasithea Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons